SINTX Technologies Announces Publication of Study Confirming Superior Performance of Silicon Nitride in Cervical Spine Fusion
SINTX Technologies (NASDAQ: SINT) announced the publication of a peer-reviewed study demonstrating the biomechanical advantages of silicon nitride in anterior cervical discectomy and fusion (ACDF) procedures. The research, conducted by SRM Institute of Science and Technology in collaboration with SINTX, compared various cage designs and materials used in cervical spine fusion.
The study highlighted several key advantages of silicon nitride over traditional materials like PEEK and titanium:
- Reduced cage subsidence and exceptional load-bearing capability
- Enhanced stress distribution and lower risk of adjacent segment degeneration
- Superior osseointegration properties compared to biologically inert PEEK
- Better post-surgical imaging capabilities due to radiolucency
With global spinal fusion procedures expected to exceed $10 billion annually, SINTX aims to leverage these findings to expand the adoption of silicon nitride-based medical devices in orthopedic applications.
SINTX Technologies (NASDAQ: SINT) ha annunciato la pubblicazione di uno studio sottoposto a revisione paritaria che dimostra i vantaggi biomeccanici del nitruro di silicio nelle procedure di discectomia cervicale anteriore e fusione (ACDF). La ricerca, condotta dall'Istituto SRM di Scienza e Tecnologia in collaborazione con SINTX, ha confrontato vari design e materiali delle gabbie utilizzate nella fusione della colonna cervicale.
Lo studio ha evidenziato diversi vantaggi chiave del nitruro di silicio rispetto ai materiali tradizionali come PEEK e titanio:
- Riduzione della subsidenza della gabbia e capacità di carico eccezionale
- Distribuzione dello stress migliorata e rischio ridotto di degenerazione del segmento adiacente
- Proprietà di osteointegrazione superiori rispetto al PEEK biologicamente inerte
- Migliori capacità di imaging post-chirurgico grazie alla radiolucenza
Con le procedure di fusione spinale globali che si prevede supereranno $10 miliardi all'anno, SINTX mira a sfruttare questi risultati per espandere l'adozione di dispositivi medici a base di nitruro di silicio nelle applicazioni ortopediche.
SINTX Technologies (NASDAQ: SINT) anunció la publicación de un estudio revisado por pares que demuestra las ventajas biomecánicas del nitruro de silicio en los procedimientos de discectomía cervical anterior y fusión (ACDF). La investigación, realizada por el Instituto SRM de Ciencia y Tecnología en colaboración con SINTX, comparó varios diseños y materiales de jaulas utilizados en la fusión de la columna cervical.
El estudio destacó varias ventajas clave del nitruro de silicio sobre materiales tradicionales como PEEK y titanio:
- Reducción de la subsistencia de la jaula y capacidad de carga excepcional
- Mejor distribución del estrés y menor riesgo de degeneración del segmento adyacente
- Propiedades de osteointegración superiores en comparación con el PEEK biológicamente inerte
- Mejores capacidades de imagen postquirúrgica debido a la radiolucidez
Con las procedimientos de fusión espinal globales que se espera superen $10 mil millones anualmente, SINTX busca aprovechar estos hallazgos para expandir la adopción de dispositivos médicos basados en nitruro de silicio en aplicaciones ortopédicas.
SINTX Technologies (NASDAQ: SINT)는 전방 경추 디스크 절제 및 융합(ACDF) 절차에서 실리콘 나이트라이드의 생체역학적 이점을 입증하는 동료 검토 연구의 발표를 알렸습니다. SRM 과학기술 연구소가 SINTX와 협력하여 수행한 이 연구는 경추 융합에 사용되는 다양한 케이지 디자인과 재료를 비교했습니다.
이 연구는 전통적인 재료인 PEEK와 티타늄에 비해 실리콘 나이트라이드의 여러 주요 이점을 강조했습니다:
- 케이지 침하 감소 및 뛰어난 하중 지지 능력
- 스트레스 분산 향상 및 인접 세그먼트 퇴행 위험 감소
- 생물학적으로 비활성인 PEEK에 비해 우수한 골융합 특성
- 방사선 투과성으로 인한 수술 후 영상 능력 향상
전 세계적으로 척추 융합 절차가 매년 $10억을 초과할 것으로 예상되는 가운데, SINTX는 이러한 발견을 활용하여 정형외과 응용 분야에서 실리콘 나이트라이드 기반 의료 기기의 채택을 확대할 계획입니다.
SINTX Technologies (NASDAQ: SINT) a annoncé la publication d'une étude évaluée par des pairs démontrant les avantages biomécaniques du nitrure de silicium dans les procédures de discectomie cervicale antérieure et de fusion (ACDF). La recherche, menée par l'Institut SRM de Science et Technologie en collaboration avec SINTX, a comparé divers designs et matériaux de cages utilisés dans la fusion de la colonne cervicale.
L'étude a mis en évidence plusieurs avantages clés du nitrure de silicium par rapport aux matériaux traditionnels tels que le PEEK et le titane :
- Réduction de l'enfoncement de la cage et capacité de charge exceptionnelle
- Meilleure distribution des contraintes et risque réduit de dégénérescence des segments adjacents
- Propriétés d'ostéointégration supérieures par rapport au PEEK biologiquement inerte
- Meilleures capacités d'imagerie post-chirurgicale grâce à la radiolucidité
Avec les procédures de fusion vertébrale dans le monde entier qui devraient dépasser 10 milliards de dollars par an, SINTX vise à tirer parti de ces résultats pour élargir l'adoption de dispositifs médicaux à base de nitrure de silicium dans les applications orthopédiques.
SINTX Technologies (NASDAQ: SINT) gab die Veröffentlichung einer von Fachkollegen geprüften Studie bekannt, die die biomechanischen Vorteile von Siliziumnitrid bei anteriorer zervikaler Diskektomie und Fusion (ACDF) Verfahren demonstriert. Die Forschung, die vom SRM Institute of Science and Technology in Zusammenarbeit mit SINTX durchgeführt wurde, verglich verschiedene Käfigdesigns und Materialien, die bei der Fusion der Halswirbelsäule verwendet werden.
Die Studie hob mehrere wichtige Vorteile von Siliziumnitrid im Vergleich zu traditionellen Materialien wie PEEK und Titan hervor:
- Reduzierte Käfigabsenkung und außergewöhnliche Tragfähigkeit
- Verbesserte Stressverteilung und geringeres Risiko einer Degeneration benachbarter Segmente
- Überlegene Osteointegrations-Eigenschaften im Vergleich zu biologisch inertem PEEK
- Bessere postchirurgische Bildgebungsfähigkeiten aufgrund von Radioluzidität
Da die globalen Wirbelsäulenfusionsverfahren voraussichtlich jährlich 10 Milliarden US-Dollar übersteigen werden, plant SINTX, diese Erkenntnisse zu nutzen, um die Akzeptanz von medizinischen Geräten auf Siliziumnitrid-Basis in der Orthopädie zu erweitern.
- Published peer-reviewed study validates superior performance of silicon nitride technology
- Product demonstrates multiple competitive advantages over existing PEEK and titanium solutions
- Large market opportunity with global spinal fusion procedures exceeding $10 billion annually
- Technology shows potential for reducing surgical complications and improving patient outcomes
- No immediate revenue impact or commercialization timeline mentioned
- Still requires strategic partnerships for market adoption
Insights
SINTX's published study represents a significant technological validation for their silicon nitride material in cervical spine fusion applications. The finite element analysis conducted with SRM Institute demonstrates specific biomechanical advantages over industry-standard materials like PEEK and titanium.
Four key technical advantages stand out: reduced cage subsidence (minimizing implant sinking into vertebral endplates), improved stress distribution (reducing adjacent segment degeneration), enhanced osseointegration (promoting stronger bone fusion), and superior imaging compatibility (enabling clearer post-surgical assessment).
From a technical perspective, these properties address critical failure points in current spinal fusion procedures. Subsidence and inadequate fusion are among the most common reasons for revision surgeries, occurring in approximately 14-30% of traditional implants. Silicon nitride's osteoconductive properties could potentially reduce these complications.
While this study provides strong biomechanical evidence, it's important to note it uses finite element analysis rather than clinical outcomes data. The theoretical advantages demonstrated here will need validation through patient outcomes studies to fully establish clinical superiority in real-world applications.
This publication strengthens SINTX's competitive positioning in the $10 billion global spinal fusion market. Silicon nitride represents a potential next-generation biomaterial that addresses limitations of both PEEK (poor osseointegration) and titanium (imaging artifacts).
The timing is strategic as the cervical spine segment seeks differentiated technologies. With approximately 400,000 ACDF procedures performed annually in the US alone, even modest market penetration represents substantial revenue potential for a microcap company like SINTX (
However, biomechanical validation alone rarely drives immediate adoption. SINTX faces significant commercialization hurdles including: surgeon education requirements, potential premium pricing constraints, entrenched competitor relationships, and the need for clinical outcome data to support reimbursement arguments.
The study serves primarily as scientific marketing collateral to support SINTX's partnership strategy. Their approach of engaging "strategic partners" rather than direct commercialization acknowledges the significant capital requirements for market entry in this space. The success of this approach depends on their ability to leverage this evidence to secure meaningful industry partnerships with established spine players who can navigate regulatory and market access challenges.
SALT LAKE CITY, Utah, March 19, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics for medical device and technical applications, announced today the publication of a new peer-reviewed study demonstrating the biomechanical advantages of silicon nitride in anterior cervical discectomy and fusion (ACDF) procedures.
The study, titled Biomechanical Evaluation of Cervical Interbody Fusion Cages for Anterior Cervical Discectomy and Fusion With Variations in Morphology, was conducted by researchers at SRM Institute of Science and Technology in collaboration with SINTX Technologies. Using finite element analysis, the study compared various cage designs and materials used in cervical spine fusion procedures. The results highlight silicon nitride’s superior biomechanical performance, particularly in reducing implant subsidence, improving load distribution, and enhancing spinal stability.
Key Commercial Findings for Spinal Medical Devices
The findings of this study complement key conclusions from previous studies of the silicon nitride biomaterial and reinforce the unique advantages of silicon nitride over traditional spinal implant biomaterials like PEEK (polyetheretherketone) and titanium, including:
- Reduced Cage Subsidence – Silicon nitride exhibited exceptional load-bearing capability, minimizing the risk of implant subsidence, a common complication in spinal fusion surgery.
- Improved Biomechanical Stability – The study confirmed that silicon nitride interbody fusion cages provide enhanced stress distribution and reduce the risk of adjacent segment degeneration.
- Superior Osseointegration – Unlike PEEK, which is biologically inert and can induce formation of scar tissue at the implant interface, silicon nitride promotes stronger bone fusion due to its osteoconductive and antimicrobial properties.
- Enhanced Imaging and Safety – Unlike metal implants, silicon nitride offers radiolucency, enabling better post-surgical imaging and reducing artifacts in MRI and CT scans.
Implications for the Spinal Implant Market
“This study provides more compelling evidence of the biomechanical and clinical benefits of silicon nitride for spinal fusion applications,” said Eric Olson, CEO of SINTX Technologies. “As the demand for advanced spinal implants grows, we believe our proprietary silicon nitride biomaterial presents a transformative solution for improving long-term patient outcomes while reducing surgical complications.”
With global spinal fusion procedures expected to surpass
For more information, please visit www.sintx.com
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
What are the key advantages of SINT's silicon nitride over PEEK in spinal fusion?
How does SINTX's silicon nitride technology improve post-surgical imaging?
What is the market potential for SINTX's spinal fusion technology?
What clinical benefits does SINT's silicon nitride offer for ACDF procedures?
